LEXINGTON, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (TTOO, Financial), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences.
The first conference is the 3rd Annual Needham MedTech 1x1 Conference, which is being held August 7 in Boston. This conference will allow institutional investors to meet with the Company but does not include a formal presentation. The second conference is the Canaccord Genuity 38th Annual Growth Conference, which is being held August 8-9 in Boston.
The Company is scheduled to present at the Canaccord conference on Thursday, August 9, 2018 at 11:00 a.m. ET and will be available for one-on-one meetings during the conference. The presentation will be webcast live and available for replay and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.
About T2 Biosystems:
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. For more information, please visit www.t2biosystems.com.
Media Contact:
Gina Kent, Vault Communications
[email protected]
610-455-2763
Investor Contact:
Matthew Clawson, W2O Group
[email protected]
949-370-8500
